SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs with significant premiums reported in Shanghai. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers, leading many to anticipate a massive "silver squeeze" and a re-rating of its value. While bulls foresee further exponential gains, some community members anticipate a near-term pullback after its rapid ascent.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors celebrate the recent FDA approval of YARTEMLEA, the first and only treatment for a life-threatening post-transplant complication, sparking a fervent discussion on its potential. The community believes the stock is significantly undervalued, pointing to a strategic partnership with Novo Nordisk and a strong pipeline, fueling speculation of a massive short squeeze and potential buyout. Anticipation is high for further details on commercialization plans and pricing, with many urging long-term holds.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending amidst significant network upgrades, including the rollout of Polkadot 2.0 featuring elastic scaling, a new supply cap for DOT with halving emissions, and a migration of governance and staking to its Asset Hub chain. Community sentiment is notably divided, with proponents viewing these tokenomic shifts as strong bullish catalysts for long-term growth and others expressing deep skepticism regarding past performance and future prospects. These developments also unfold alongside discussions of its interoperability within the broader crypto ecosystem and ongoing dialogues around potential crypto ETF approvals.

Direxion Shares ETF Trust - Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares is trending as the broader S&P 500 index recently achieved new record highs, fueling fervent bullish sentiment. The community is actively debating whether this marks the continuation of an upward rally, prompting many to buy dips and leverage for amplified gains. While economic indicators and discussions around central bank policies add context, traders are keenly focused on riding the market's momentum.

A community-driven memecoin created to protect and empower crypto users, CTOs, and low-marketcap gems. Our ecosystem features weekly crypto talks/hosting services, a “Most Wanted" scam tracker, and a "Portfolio" with partnered projects. We help others succeed through long-term partnerships and services.   Weekly Hosting: a weekly hosting service where the team and community come together to talk about crypto and project updates. We will invite guests from rugged projects who want to talk/share insight, invite CTO/low market cap projects to come speak about what they are doing, and give dedicated time for partnered projects to speak on updates for our listeners.   Portfolio: a webpage designated to embrace CTOs or smaller cap projects with an established following.  Partnered projects commit to a discussed rate to help fuel growth of the RCON token and their own, through a structured revenue distribution model (detailed below).  Tokens will be held as long as the partnered project remains active.  12.5% buys RCON coin and burns 12.5% sent to RCON marketing wallet 12.5% used for LP/Pairing [RCON and partnered token] on ORCA 12.5% dedicated to community outreach 50% buys and holds initial value of partnered token  Most Wanted: a webpage designated to expose chronic offenders / scammers / ruggers.  Our project can help those navigate the cryptocurrency space safely.

Recon Raccoon

RCON CRYPTO is gaining attention as the community actively discusses significant portions of its token supply being locked, earmarked for future Centralized Exchange listings and long-term team vesting. Investors are highlighting the project's committed team and its detailed vision as pivotal factors driving interest and future potential.

Harmony Gold Mining Co. Ltd. is a world-class gold-mining and exploration company with a copper footprint. The company involves nine deep-level mines, an open-pit mining operation and several surface retreatment facilities. It operates through the following segments: Tshepong North, Tshepong South, Moab Khotsong, Joel, Doornkop, Target 1, Kusasalethu, Masimong, Mponeng, Mine Waste Solutions and Hidden Valley. The company was founded on August 25, 1950 and is headquartered in Randfontein, South Africa.

Harmony Gold Mining Co Ltd - ADR

Harmony Gold Mining Co. Ltd.

Harmony Gold Mining is trending as surging gold prices, reaching record highs, fuel bullish sentiment across the precious metals sector. Investors are actively discussing HMY's significant undervaluation, strategic acquisitions like MAC Copper, and strong earnings reports, positioning it as a potential safe-haven play with substantial upside. However, some market participants express caution regarding a potential gold oversupply from aggressive mining.

abrdn ETF - abrdn Physical Silver Shares ETF

SIVR is trending as silver prices achieve significant highs, driven by strong investor demand for safe-haven assets and expectations of loosening monetary policy. The community is actively discussing silver's breakout, citing perceived undervaluation, tightening supply, and increasing industrial demand amid global economic uncertainties. Many anticipate continued upward movement, seeing silver as a critical hedge against inflation and a weaker dollar.

Anglogold Ashanti Plc is a holding company, which engages in the operation and exploration of gold mining projects through its subsidiary. Its asset portfolio includes production from Argentina, Australia, Brazil, the Democratic Republic of Congo, Ghana, Guinea, and Tanzania. The firm also produces silver and sulfuric acid as by-products. The company was founded in 1998, and is headquartered in Staines-upon-Thames, the United Kingdom.

AngloGold Ashanti Plc.

AngloGold Ashanti Ltd.

AngloGold Ashanti is trending sharply higher, fueled by significant stock appreciation, strong production growth, and strategic acquisitions in key mining regions. The community is largely bullish, highlighting robust free cash flow and positive analyst ratings, although some voices express concern about gold oversupply potentially impacting future prices.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is a prominent talking point as the market reacts to escalating global tensions and China's increased control over critical mineral exports. Investors are keenly focused on UAMY's established role as a key domestic supplier, particularly for military-grade antimony, and its ongoing capacity expansion to meet growing strategic demand amidst skepticism surrounding emerging competitors.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) is currently trending as investors eagerly anticipate upcoming monthly dividend payouts, often citing them as a reliable source of income. The community actively debates JEPQ's performance and tax efficiency against similar covered-call ETFs, with many viewing recent price dips as attractive buying opportunities for long-term retirement portfolios. Its strategy of generating income from Nasdaq-listed equities continues to appeal to those seeking steady distributions amid broader market fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Artelo Biosciences, Inc. (ARTL) surged 57% on Monday afternoon after the company announced positive preclinical data highlighting the potential of its drug candidate in treating depression and anxiety.The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with leading antidepressant medication, Sertraline (Zoloft).ART12.11 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.artelobio.com/news-events/press-releases/detail/153/artelo-biosciences-announces-positive-preclinical-efficacy">improved</a> sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels.However, unlike Sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, the company added.<a href="https://stocktwits.com/symbol/ARTL">Artelo</a> added that the findings demonstrate the candidate’s potential as a candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing selective serotonin reuptake inhibitor therapies like Sertraline.ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP).Prior preclinical research studies in animals with ART12.11 demonstrated greater behavioral and pharmacokinetic results compared to Cannabidiol or Epidiolex.Artelo CEO Gregory D Gorgas said that although strong antidepressant effects were noted with ART12.11 in prior studies, the company is “especially encouraged” by these new comparative findings.On Stocktwits, retail sentiment around Artelo, however, fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_12_27_08_PM_png_b2e63d4064.webp" alt="ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>ARTL stock is up by about 148% this year and by about 99% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-buying-hit-3-4-trillion-in-the-first-half-of-2025-yet-market-chatter-has-faded/chFtYldR5fx">Retail Buying Hit $3.4 Trillion In The First Half Of 2025, Yet Market Chatter Has Faded</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 

Equity

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 


Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.ART26.12 is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage caused by certain chemotherapy drugs, leading to sensory, motor, or autonomic dysfunction.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107392/0/en/Artelo-Biosciences-Announces-Positive-First-in-Human-Data-for-ART26-12-a-Novel-Non-Opioid-Treatment-Candidate-for-Persistent-Pain.html">said</a> that all adverse events identified during the in-human trial were mild, transient, and self-resolving. Furthermore, the study demonstrated predictable pharmacokinetics for the drug.Pharmacokinetics is defined as the quantitative analysis of the processes of drug absorption, distribution, and elimination that determine the time course of drug action in response to an administered drug dose.The company said that complete dose-exposure profiles were explored, and tests confirmed dose-dependent, linear absorption across the evaluated range.Andrew Yates, Chief Scientific Officer at Artelo, said that the company is “particularly pleased” that the safety and pharmacokinetic profile generated from ART26.12’s non-clinical studies translated well to the human experience.According to Artelo, the chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 2030, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia.The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.On Stocktwits, retail sentiment around ARTL jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_30_at_1_46_11_PM_png_54bfa7b48c.webp" alt="ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits" width="624" height="62"><figcaption>ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, flagged that the company will need cash to progress its pipeline, and hence, dilution is likely.<stembedurl>https://stocktwits.com/ElPutoToro/message/619463192</stembedurl>The company had cash and investments totaling only $0.7 million as of the end of the first quarter.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up by about 135% this year and by about 85% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q2-deliveries-expected-to-fall-below-consensus-jpmorgan-underscores-sizable-shortfall/chmZF6zRR7Q">Tesla Q2 Deliveries Expected To Fall Below Consensus, JPMorgan Underscores A ‘Sizable’ Shortfall</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial

Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.

The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.


Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ARTL News

ARTLArtelo Biosciences Inc